Royalty Pharma reports second quarter 2026 results
NEW YORK, NY, August 5, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.
Investors
Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.
Latest results
Portfolio metrics
35+
Approved products
19
Development-stage therapies
16
Blockbuster products (>$1bn in annual sales)
~13year
Portfolio duration
Financial metrics
$3.3bn
Portfolio Receipts
(2025)
(2025)
$3.0bn
Adjusted EBITDA
(2025)
(2025)
$2.5bn
Average annual capital deployed (2020-2025)
$4.7bn
Announced value of transactions (2025)
Stock information
RPRX
${{TradePrice}}
{{TradeDate}}
Latest quarterly earnings
Q2 2026
Corporate presentation
Latest releases
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
NEW YORK, NY, August 3, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026.
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
NEW YORK, NY, July 22, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront.
Royalty Pharma declares third quarter 2026 dividend
NEW YORK, NY, July 17, 2026 — The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.
